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Tsoupras and colleagues have postulated, in a recent review in Nutrients, that the key to reducing
the incidence of cardiovascular disease is to control the activities of inflammatory mediators such
as platelet-activating factor (PAF) by diet, exercise, and healthy lifestyle choices [1]. We agree with
this sensible conclusion, which is based on the extensive scientific literature. The authors argue that
their proposal is contrary to the lipid (or cholesterol) hypothesis. This supposes that the reduction of
plasma lipid concentrations will reduce new incidents of cardiovascular disease, a concept developed
over many decades from the recommendation in 1976 that a combined drug/diet regimen in a study
with large numbers of male hyperlipidemic subjects would be necessary to test the accuracy of the
hypothesis [2]. Following extensive studies with the statins as lipid-lowering drugs, the accumulation
of evidence for the lipid hypothesis was then presented in 2006 with Steinberg concluding that the
controversy was solved by the results of these studies, stating that “The cholesterol controversy could
have been resolved much earlier if all of us had looked at all of the evidence” [3]. However, this
conclusion on the lipid hypothesis continues to arouse passionate arguments, as shown in the review
by Tsoupras and colleagues [1] and in other recent reviews [4].
Chronic disease of the cardiovascular system is not just a modern phenomenon. Atherosclerosis
has been identified using computed tomography in ancient Egyptian, Peruvian, and Native American
mummies with the Egyptian Princess Ahmose-Meryet-Amon who lived around 1580–1550 B.C. as
the earliest human known to have had coronary artery disease [5,6]. These findings led to the
question “Might the chronic inflammatory load of ancient times secondary to infection have resulted
in atherosclerosis?” [5]. The scientific basis of inflammation in atherosclerosis also has a long history.
The influential European pathologists of the 19th century, Rudolf Virchow and Carl von Rokitansky,
described inflammatory changes in atherosclerosis, with Virchow supporting the primary role of
inflammation while von Rokitansky argued that incorporated mural thrombosis was the key pathogenic
process in atherosclerosis [7]; both mechanisms are incorporated in current concepts of the development
of atherosclerosis [8]. Insights provided by molecular and cellular biology into the complexity of
atherosclerosis have given a better idea of the mechanisms that link risk factors such as low-density
lipoproteins (LDL), hypertension, cigarette smoking, diabetes, and inflammation to the clinical
disease [9].
What is the role of cholesterol in cardiovascular health and disease? As noted by Tsoupras and
co-authors [1], cholesterol is essential for the normal function of cells including the structural makeup
and fluidity of cell membranes, signal transduction, intracellular transport, nerve conduction, signaling
pathways through lipid rafts and caveolae, and, as the precursor for vitamin D, steroid hormones,
and bile salts. Most of the cholesterol in humans comes from endogenous production, supporting
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the finding by Ancel Keys and co-workers that changing dietary cholesterol in humans produced
minor effects on serum cholesterol concentrations [10]. As lipid-soluble compounds, cholesterol and
triglycerides are transported in lipoproteins that are necessary for absorption of dietary lipids from the
small intestine, transport of lipids to peripheral tissues, and transport of lipids back to the liver and
intestine. LDL that transport most of the cholesterol are considered pro-atherogenic. The connection
between cholesterol and atherogenesis was first reported in 1913 by Anitschkow and Chalatow in
rabbits fed egg yolk [11]. But do dietary cholesterol intakes and serum cholesterol concentrations relate
to human atherosclerosis? In 1958, Ancel Keys and his team started the Seven Countries Study (SCS)
which reported marked differences in rates of coronary heart disease events and deaths among cohorts
and strong associations of average dietary features and blood cholesterol concentrations with those
rates [12,13]. The controversies from these conclusions are on-going [14]. Further, the role of dietary
fat intakes on cardiovascular disease continues to be argued. As a recent example, the Prospective
Urban Rural Epidemiology (PURE) study results from 135,335 subjects over five continents that intake
of total fat and individual types of fat was unrelated to cardiovascular disease or mortality [15] have
been labeled as “misleading” [16].
If cholesterol is important in cardiovascular disease, then selective inhibition by the statins
of HMG-CoA reductase, a rate-limiting step in endogenous cholesterol synthesis, should decrease
cardiovascular risk. This result has been found in many, but not all, studies. It is now 25 years since
the publication of the Scandinavian Simvastatin Survival Study (4S) showing that simvastatin reduced
LDL-cholesterol by 35% with a relative risk of death of 0.70 with 5-year treatment in 4,444 subjects
with angina pectoris or previous myocardial infarction and serum cholesterol concentrations of 5.5 to
8 mmol/L [17]. Statin therapy is recommended for primary prevention of stroke with each decrease of
1 mmol/L in serum cholesterol concentrations equating to a reduction in relative risk by 21% [18]. Statin
therapy reduced the risk of heart failure in patients with cardiovascular risk factors but without heart
failure; however, statins did not reduce rates of cardiovascular death in patients with heart failure [19].
In contrast, Cochrane meta-analyses of cholesterol lowering with statins in peripheral arterial disease
of the lower extremities in acute coronary syndromes reported no benefit [20,21]. Similarly, the lack
of an association between LDL-cholesterol and mortality in the elderly has been reported through
systematic review [22]. Importantly, statins produce a range of pleiotropic effects in addition to
inhibition of cholesterol synthesis, especially to reduce inflammatory markers such as C-reactive
protein, which may be important in reducing the formation of atherosclerotic plaque [23]. However,
statins do not completely prevent atherosclerotic vascular disease. If atherosclerosis is a complex
inflammatory disorder, then anti-inflammatory therapy on top of intense lipid-lowering treatment
should lower the risk of acute cardiovascular events. This has now been proved with the Canakinumab
Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial with targeted inhibition of interleukin
(IL)-1β with canakinumab [24]. Further, the residual risk after canakinumab may be related to
the persistence of high concentrations of other inflammatory cytokines such as IL-6 and IL-18 [25].
Novel anti-inflammatory compounds are in Phase II and III trials for treatment of atherosclerosis [26].
The modulatory role of inflammation is now unambiguous, showing that “inflammation provides
a pathway that mechanistically links alterations in traditional risk factors and modifications in the
biology of the artery wall that give rise to atherosclerosis and its complications” [27].
If inflammation is critical in atherosclerosis, then resolving chronic inflammation could be
the next approach to decrease atherosclerotic risk. Under normal physiological circumstances,
inflammation resolves after the clearance of infection or injurious agents; however, in chronic
conditions, the inflammatory response continues, leading to continuing tissue damage [28]. Resolution
of inflammation is controlled by specialized proresolving mediators such as lipoxins, resolvins,
protectins, and maresins [29]. The development of selective compounds that are effective in promoting
resolution of inflammation will further support the role of inflammation in atherosclerosis.
The formation of inflammatory atherosclerotic lesions follows the accumulation of lipids in
the vascular wall from the circulation. Plasma cholesterol concentrations may then be a biomarker
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rather than the cause for the development of atherosclerosis, as treatment of inflammation, either
prevention or reversal, is the key therapeutic aim. Chronic inflammation has been proposed as a major
player in the development and progression of other chronic diseases [28,30–32]. Further, targeting
chronic inflammation has been suggested as an intervention to reduce aging-related complications and
improving tissue repair [28,33].
Chronic inflammation may be managed by lifestyle interventions and dietary modifications to
restrict progression of tissue damage. Many dietary interventions have been suggested to improve
outcomes in chronic diseases [34–43]. The main aim of these dietary interventions is to lower
inflammation in the body. Low prevalence of cardiovascular mortality in the Mediterranean cohorts
of SCS was correlated to their lifestyle and Mediterranean diet [44,45]. The Prevención con Dieta
Mediterránea (PREDIMED) trial provided strong evidence for vegetable-based Mediterranean diets
with increased unsaturated fat and polyphenols in the prevention of cardiovascular disease [46].
The PREDIMED trial used the Dietary Inflammatory Index to show an increased risk of cardiovascular
events with a proinflammatory diet [47]. The Okinawan diet, characterized by low caloric intake;
high consumption of vegetables (particularly root and green–yellow vegetables), legumes, and fish
products; low consumption of meat products and dairy products; low fat intake; low-glycemic index
carbohydrates; high fiber intake; and moderate alcohol consumption, modulates insulin signaling
and inflammatory pathways [43]. The Okinawan diet has also been suggested to reduce risks
for aging-associated chronic diseases and to promote longevity [43]. The Nordic diet, which is
similar in composition to the Mediterranean diet but less researched for health benefits, has shown
anti-inflammatory effects [42].
These diets and others such as DASH (Dietary Approaches to Stop Hypertension) and portfolio
diets have the same aim of reducing systemic inflammation [43]. The reduction in chronic inflammation
would reduce the tissue damage to prevent disease progression [33]. Improvement in tissue status,
along with anti-inflammatory effects, would improve overall metabolic health of an individual. As an
example, the Mediterranean diet decreased hepatic fat content, a risk factor for metabolic syndrome,
type 2 diabetes, and coronary heart disease [48]. Complete removal of dietary meat as in vegetarian diets
reduces body mass, improves plasma lipid profile, gut microbiota, and insulin sensitivity, and decreases
the incidence of cardiovascular disease, stroke, metabolic syndrome, arteriosclerosis, diabetes, and
cancer. However, the vegetarian diet has been associated with development of hyperhomocysteinemia,
protein deficiency, anemia, decreased creatinine content in muscles, menstrual disruption in women,
and increased risk of osteoporosis and bone fractures [49–58]. The role of exercise and physical activity
in obesity reduction and management have been well established [59,60]. With an increased caloric
intake, increasing energy expenditure through exercise and physical activity will help maintain the
weight status [60]. Moreover, a meta-analysis suggested that engaging in exercise training decreased
C-reactive protein regardless of the age or sex of the individual [61]. This meta-analysis also concluded
that the improvements in C-reactive protein were greater with a decrease in body mass index or %
body fat [61]. Other studies have also reported anti-inflammatory benefits of physical activity and
exercise [62–66], which would certainly help reduce the risk of chronic diseases.
Tsoupras and colleagues have thoroughly reviewed the role of PAF in controlling inflammation.
They have clearly listed the roles PAF can play in normal physiological conditions and in atherosclerosis
and cardiovascular diseases [1]. The question now is whether PAF is the most important inflammatory
mediator that can be controlled for preventing chronic inflammatory diseases. The answer to
this question is likely ‘no’ as there are many other regulators of inflammatory pathways [66–71].
Thus, identifying and targeting selective inflammatory pathways related to the cause and stage of
disease development in groups of individuals could provide a more effective solution for treating
inflammation-induced chronic diseases.
In conclusion, we agree that the logical way to decrease the inflammation-induced risk of chronic
diseases such as atherosclerosis is to decrease pro-inflammatory inputs. Using drugs, diets, and exercise
could provide the anti-inflammatory mechanisms to achieve these targets. However, consideration
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of the wide range of inflammatory mediators in addition to PAF is needed to reduce the risk in
populations with multifactorial causes for the initiation of inflammation. Finally, while the concept
of functional foods allows the testing and eventual use of foods for chronic disease prevention and
management, attributing the saying to Hippocrates that “Let food be thy medicine and medicine be
thy food” appears to be a historical, if oft-repeated, misquotation [72].
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